Indeed, simultaneous assessment of both biomarkers provides greater benefit allowing to draw conclusions not only as to size of the damaged area, correlation with functional deficit, and prognosis (high level of H-FABP), but also as to the type of stroke (e.g., lacunar or small-vessel disease, when high level of B-FABP). The gene discussed is FABP3; the disease is stroke disorder.